ABSTRACT
Pyoderma gangrenosum (PG) is a neutrophilic dermatosis characterized by ulcerative painful lesions with violaceous undermined borders. Up to 75% of PG cases develop in association with an underlying systemic disease. Monoclonal gammopathy is reportedly a concomitant condition with PG, with studies indicating immunoglobulin (Ig) A gammopathy as the most common. Whether gammopathy is associated with PG or is an incidental finding has been debated. We sought to investigate the association and characteristics of gammopathy in patients with PG. We retrospectively identified PG patients at our institution from 2010 to 2022 who were screened for plasma cell dyscrasia. Of 106 patients identified, 29 (27%) had a gammopathy; subtypes included IgA (41%), IgG (28%), and biclonal (IgA and IgG) (14%). Mean age was similar between those with and without gammopathy (60.7 vs. 55.9 years; P = .26). In addition, hematologic or solid organ cancer developed in significantly more patients with vs. without gammopathy (8/29 [28%] vs. 5/77 [6%]; P = .003). Among the subtypes of gammopathy, IgG monoclonal gammopathy had the highest proportion of patients with subsequent cancer development (4 of 8 patients, 50%). Study limitations include a retrospective, single-institution design with a limited number of patients. Overall, our data show a high prevalence of gammopathy in patients with PG; those patients additionally had an increased incidence of cancer, especially hematologic cancer.
Subject(s)
Paraproteinemias , Pyoderma Gangrenosum , Humans , Pyoderma Gangrenosum/diagnosis , Pyoderma Gangrenosum/epidemiology , Retrospective Studies , Middle Aged , Female , Male , Paraproteinemias/complications , Paraproteinemias/diagnosis , Paraproteinemias/epidemiology , Paraproteinemias/immunology , Aged , Immunoglobulin A/blood , Immunoglobulin A/immunology , Adult , Immunoglobulin G/blood , Immunoglobulin G/immunologyABSTRACT
The acquired chronic demyelinating neuropathies include a growing number of disease entities that have characteristic, often overlapping, clinical presentations, mediated by distinct immune mechanisms, and responding to different therapies. After the discovery in the early 1980s, that the myelin associated glycoprotein (MAG) is a target antigen in an autoimmune demyelinating neuropathy, assays to measure the presence of anti-MAG antibodies were used as the basis to diagnose the anti-MAG neuropathy. The route was open for describing the clinical characteristics of this new entity as a chronic distal large fiber sensorimotor neuropathy, for studying its pathogenesis and devising specific treatment strategies. The initial use of chemotherapeutic agents was replaced by the introduction in the late 1990s of rituximab, a monoclonal antibody against CD20+ B-cells. Since then, other anti-B cells agents have been introduced. Recently a novel antigen-specific immunotherapy neutralizing the anti-MAG antibodies with a carbohydrate-based ligand mimicking the natural HNK-1 glycoepitope has been described.
Subject(s)
Autoantigens/immunology , Demyelinating Autoimmune Diseases, CNS/immunology , Myelin-Associated Glycoprotein/immunology , Polyradiculoneuropathy/immunology , Adenine/analogs & derivatives , Adenine/therapeutic use , Animals , Autoantibodies/blood , Autoantibodies/immunology , B-Lymphocyte Subsets/immunology , CD57 Antigens/immunology , Demyelinating Autoimmune Diseases, CNS/diagnosis , Demyelinating Autoimmune Diseases, CNS/therapy , Epitopes/immunology , Gait Disorders, Neurologic/immunology , Humans , Immunosuppressive Agents/therapeutic use , Immunotherapy , Lenalidomide/therapeutic use , Mammals , Mice , Molecular Mimicry , Myelin Sheath/chemistry , Myelin Sheath/immunology , Myelin Sheath/ultrastructure , Nerve Fibers, Myelinated/immunology , Nerve Fibers, Myelinated/pathology , Nervous System Autoimmune Disease, Experimental/immunology , Paraproteinemias/immunology , Paraproteins/immunology , Piperidines/therapeutic use , Plasma Exchange , Polyradiculoneuropathy/diagnosis , Polyradiculoneuropathy/therapy , Ranvier's Nodes/chemistry , Ranvier's Nodes/immunology , Rats , Rituximab/therapeutic useABSTRACT
INTRODUCTION: The measurement of serum free light chain (FLC) represents a fundamental aspect on the assessment of patients with monoclonal gammopathies (MG). Different analytical methods for FLC have become available with the possibility to obtain different value with a substantial impact on the assessment of patients with MG. This study aimed to evaluate FLC results obtained with two different assays and how the difference value obtained can impact in the patient's assessment. MATERIALS AND METHODS: Ninety-three patient serum samples that underwent analysis for FLC with two different methods, Serum Freelite (The Binding Site, Birmingham, UK) and N-Latex FLC (Siemens, Marburg, Germany), were included in this retrospective study. Statistical analysis was performed to evaluate correlation, difference, and the grade of concordance between the results obtained with the two methods. RESULTS: Significant statistical differences between the results obtained from the two methods were found (P < 0.05). A good correlation was found (0.99 for κ FLC, 0.95 for λ FLC, and 0.94 for the κ/λ ratio, respectively). We found a weighted kappa value of 0.65 for κ/λ ratio, 0.65 for λ FLC and 0.90 for κ FLC. A positive bias found with the Bland-Altman plot mirrors overestimation of κ FLC and κ/λ ratio with Freelite compared to N-Latex, whilst a negative bias underscores underestimation of λ FLC by Freelite compared to N-Latex. CONCLUSION: Although in general the concordance between Freelite and N-Latex appears satisfactory, several discrepancies could be evidenced and consequently the two assays are not interchangeable.
Subject(s)
Immunoglobulin Light Chains/blood , Latex/chemistry , Paraproteinemias/immunology , Adult , Aged , Aged, 80 and over , Biological Assay , Female , Humans , Immunoassay , Male , Middle Aged , Models, Statistical , Reproducibility of Results , Research Design , Retrospective Studies , Young AdultABSTRACT
OBJECTIVE: Monoclonal protein (MP) exists in various diseases, and capillary electrophoresis (CE) has been widely used to detect MP. However, there is not much research on the application value of MP in the differential diagnosis of monoclonal gammopathies. This study aimed to explore MP's cutoff value for the differential diagnosis of multiple myeloma (MM) and other monoclonal gammopathies (MGs). METHODS: A retrospective analysis of 8167 cases was conducted. Serum MP was detected by CE, and the patients' clinical information was collected from the clinical database of our hospital. RESULTS: 985 cases had MP with high peaks, and 91.1% were diagnosed with malignant diseases. The MP showed small peaks in 471 cases, and only 24.4% were diagnosed with malignant diseases. Among the MPs, the IgG-κ type was the most common type, followed by the IgG-λ, IgA-κ, IgA-λ, free λ light chain, IgM-κ, free κ light chain, double clone, and IgM-λ types. Differences in the MP of the IgG, IgA, IgM, and FLC types between the MM group and MGUS group were statistically different (P<0.01). The MP of the IgG, IgA, and FLC types showed clear specificity and sensitivity in discriminating MM from other monoclonal gammopathies in ROC curve analysis. Serum IgM had statistical significance in the differential diagnosis between WM and other MGs (P<0.01). However, there was no statistical significance in the differential diagnosis between MM and other MGs (P=0.140). The cutoff values of the MP of the IgG, IgA, and FLC types were >18.67g/L, >13.86g/L, and >10.15g/L, respectively, for the differential diagnosis of MM and other MGs. The cutoff value of the MP of IgM for the WM diagnosis was >37.75 g/L. CONCLUSION: CE has good clinical application value in the diagnosis of monoclonal gammopathies, and MP can be used in the differential diagnosis of MM and other monoclonal gammopathies.
Subject(s)
Electrophoresis, Capillary/methods , Immunoglobulin Light Chains/blood , Immunoglobulin kappa-Chains/blood , Immunoglobulin lambda-Chains/blood , Multiple Myeloma/diagnosis , Myeloma Proteins/analysis , Paraproteinemias/diagnosis , Blood Proteins/analysis , Blood Proteins/immunology , Diagnosis, Differential , Humans , Immunoglobulin Light Chains/immunology , Immunoglobulin kappa-Chains/immunology , Immunoglobulin lambda-Chains/immunology , Multiple Myeloma/blood , Multiple Myeloma/immunology , Myeloma Proteins/immunology , Paraproteinemias/blood , Paraproteinemias/immunology , ROC Curve , Retrospective StudiesABSTRACT
An unusual clonal gammopathy was reported in COVID-19 patient but whether this anomaly is related or not to the disease has not yet been clarified. To this aim, we selected a cohort of 35 COVID-19 patients swab positive and investigated serological levels of IL-6, immune response to major viral antigens and electrophoretic profile. Elevated levels of IL-6 were accompanied by a significative humoral response to viral Spike protein, revealing an altered electrophoretic profile in the gamma region. We can conclude that elevated levels of IL-6 triggers humoral response inducing a transient plasma cell dyscrasia in severe COVID-19 patients.
Subject(s)
COVID-19/complications , Interleukin-6/immunology , Paraproteinemias/virology , Aged , Antibodies, Viral/blood , COVID-19/immunology , Coronavirus Nucleocapsid Proteins/immunology , Female , Humans , Italy , Male , Paraproteinemias/immunology , Phosphoproteins/immunology , Spike Glycoprotein, Coronavirus/immunologySubject(s)
Gastrointestinal Diseases/diagnosis , Immunoglobulin Light-chain Amyloidosis/diagnosis , Paraproteinemias/complications , Waldenstrom Macroglobulinemia/complications , Biopsy , Endoscopy, Digestive System , Female , Gastrointestinal Diseases/immunology , Gastrointestinal Diseases/pathology , Humans , Immunoglobulin Light-chain Amyloidosis/immunology , Immunoglobulin Light-chain Amyloidosis/pathology , Middle Aged , Paraproteinemias/immunology , Waldenstrom Macroglobulinemia/immunologyABSTRACT
Patients with plasma cell dyscrasias (PCDs) experience an increased burden of influenza, and current practice of single-dose annual influenza vaccination yields suboptimal protective immunity in these patients. Strategies to improve immunity to influenza in these patients are clearly needed. We performed a randomized, double-blind, placebo-controlled clinical trial comparing tandem Fluzone High-Dose influenza vaccination with standard-of-care influenza vaccination. Standard-of-care vaccination was single-dose age-based vaccination (standard dose, <65 years; high dose, ≥65 years), and patients in this arm received a saline placebo injection at 30 days. A total of 122 PCD patients were enrolled; 47 received single-dose standard-of-care vaccination, and 75 received 2 doses of Fluzone High-Dose vaccine. Rates of hemagglutinin inhibition (HAI) titer seroprotection against all 3 strains (H1N1, H3N2, and influenza B) were significantly higher for patients after tandem high-dose vaccination vs control (87.3% vs 63.2%; P = .003) and led to higher seroprotection at the end of flu season (60.0% vs 31.6%; P = .04). These data demonstrate that tandem high-dose influenza vaccination separated by 30 days leads to higher serologic HAI titer responses and more durable influenza-specific immunity in PCD patients. Similar vaccine strategies may also be essential to achieve protective immunity against other emerging pathogens such as novel coronavirus in these patients. This trial was registered at www.clinicaltrials.gov as #NCT02566265.
Subject(s)
Influenza Vaccines/administration & dosage , Influenza Vaccines/immunology , Influenza, Human/immunology , Paraproteinemias/immunology , Adult , Aged , Aged, 80 and over , Double-Blind Method , Humans , Middle AgedSubject(s)
Antiphospholipid Syndrome/complications , Paraproteinemias/complications , Thrombosis/etiology , Adolescent , Adult , Aged , Antiphospholipid Syndrome/diagnosis , Antiphospholipid Syndrome/immunology , Female , Humans , Male , Middle Aged , Paraproteinemias/diagnosis , Paraproteinemias/immunology , Recurrence , Retrospective Studies , Risk Assessment , Risk Factors , Thrombosis/diagnosis , Thrombosis/immunology , Time FactorsABSTRACT
Several studies in chronic lymphocytic leukemia (CLL) patients have reported impaired immune cell functions, which contribute to tumor evasion and disease progression. However, studies on CLL-like monoclonal B-cell lymphocytosis (MBL) are scarce. In the study described here, we characterized the immune environment in 62 individuals with clinical MBL, 56 patients with early-stage CLL, and 31 healthy controls. Gene expression arrays and quantitative reverse transcription polymerase chain reaction were performed on RNA from CD4+ peripheral blood cells; serum cytokines were measured with immunoassays; and HLA-DR expression on circulating monocytes, as well as the percentages of Th1, cytotoxic, exhausted, and effector CD4+ T cells, were evaluated by flow cytometry. In addition, cell cultures of clonal B cells and CD14-enriched or -depleted cell fractions were performed. Strikingly, MBL and early-stage CLL differed in pro-inflammatory signatures. An increased inflammatory drive orchestrated mainly by monocytes was identified in MBL, which exhibited enhanced phagocytosis, pattern recognition receptors, interleukin-8 (IL8), HMGB1, and acute response signaling pathways and increased pro-inflammatory cytokines (in particular IL8, interferon γ [IFNγ], and tumor necrosis factor α). This inflammatory signature was diminished in early-stage CLL (reduced IL8 and IFNγ levels, IL8 signaling pathway, and monocytic HLA-DR expression compared with MBL), especially in those patients with mutations in IGHV genes. Additionally, CD4+ T cells of MBL and early-stage CLL exhibited a similar upregulation of Th1 and cytotoxic genes and expanded CXCR3+ and perforin+ CD4+ T cells, as well as PD1+ CD4+ T cells, compared with controls. Cell culture assays disclosed tumor-supporting effects of monocytes similarly observed in MBL and early-stage CLL. These novel findings reveal differences in the inflammatory environment between MBL and CLL, highlighting an active role for antigen stimulation in the very early stages of the disease, potentially related to malignant B-cell transformation.
Subject(s)
B-Lymphocytes/pathology , Inflammation/pathology , Leukemia, Lymphocytic, Chronic, B-Cell/pathology , Paraproteinemias/pathology , Adult , Aged , Aged, 80 and over , B-Lymphocytes/metabolism , Cell Survival , Clone Cells/metabolism , Clone Cells/pathology , Cytokines/blood , Disease Progression , Female , Gene Expression Profiling , Humans , Immunoglobulin Heavy Chains/genetics , Immunoglobulin Variable Region/genetics , Inflammation/blood , Inflammation/immunology , Leukemia, Lymphocytic, Chronic, B-Cell/blood , Leukemia, Lymphocytic, Chronic, B-Cell/immunology , Lymphocyte Subsets/immunology , Male , Middle Aged , Monocytes/cytology , Monocytes/immunology , Monocytes/metabolism , Paraproteinemias/blood , Paraproteinemias/immunology , RNA, Neoplasm/genetics , Reverse Transcriptase Polymerase Chain Reaction , Tissue Array Analysis , Tumor EscapeABSTRACT
BACKGROUND: A distal-predominant demyelinating symmetric pattern is most frequent in patients with neuropathy associated with anti-myelin-associated glycoprotein (MAG) antibodies. The literature however lacks longitudinal data to describe whether this is consistent over time. METHODS: From the Ottawa Neuromuscular Center database, we identified 23 patients with both immunoglobulin M gammopathy and anti-MAG antibodies. For median, ulnar and fibular motor conduction studies, we analyzed distal latency and amplitude, negative peak duration, terminal latency index (TLI), and conduction velocity. For median, ulnar, sural, and superficial fibular sensory conduction studies, we analyzed distal latency and amplitude. Results were compared for the earliest and the latest data sets. RESULTS: The mean time interval between the two assessment points was 6.5 years. Median and ulnar motor nerve conduction studies did not show a significant change for any of the parameters tested. There was disproportionate prolongation of median distal motor latency and reduction in TLI, compared to the ulnar nerve. Deep fibular motor conduction studies showed a marked reduction in amplitudes over time. Sensory potentials were recordable in the upper limb in less than 50% at the first study and less than 25% on the most recent study. There was an even larger attrition of recordable sural and superficial fibular sensory potentials. CONCLUSIONS: Our results highlight the stability of median and ulnar motor conduction study results over a mean observation period of 6.5 years. In contrast, lower limb motor and all sensory potentials show a marked trend toward becoming unrecordable.
Subject(s)
Autoantibodies/immunology , Median Nerve/physiopathology , Myelin-Associated Glycoprotein/immunology , Neural Conduction/physiology , Polyradiculoneuropathy/physiopathology , Ulnar Nerve/physiopathology , Aged , Aged, 80 and over , Disease Progression , Electrodiagnosis , Female , Humans , Immunoglobulin M/immunology , Male , Middle Aged , Paraproteinemias/complications , Paraproteinemias/immunology , Polyradiculoneuropathy/complications , Polyradiculoneuropathy/immunologySubject(s)
Antibodies/blood , Hypersensitivity/metabolism , Paraproteinemias/metabolism , Parasitic Diseases/metabolism , Plasma Cells/metabolism , Animals , Cellular Microenvironment , Humans , Hypersensitivity/blood , Hypersensitivity/immunology , Paraproteinemias/blood , Paraproteinemias/immunology , Parasitic Diseases/blood , Parasitic Diseases/immunology , Phenotype , Plasma Cells/immunology , Time FactorsABSTRACT
BACKGROUND: Cerebrospinal fluid (CSF) oligoclonal bands (OCB) occur in chronic or post-acute phase of inflammatory diseases of the central nervous system. OBJECTIVE: To determine whether CSF OCB in patients with neuroborreliosis (NB) are specific for borrelia burgdorferi senso lato. METHODS: We performed isoelectric focusing followed by immunoblotting in CSF of 10 NB patients and 11 controls (7 patients with multiple sclerosis, 2 patients with neuromyelitis optica spectrum disease, 1 patient with dementia and 1 patient with monoclonal gammopathy). Immunoblotting was performed using an uncoated as well as a borrelia antigen pre-coated nitrocellulose membrane (NCM). OCB were counted by visual inspection and photometric analysis. OCB were compared between uncoated und pre-coated NCM both in the NB and control group. For validation purposes inter-assay precision was determined by calculating the coefficient of variation (CV). RESULTS: Borrelia-specific OCB were found in the CSF of 9 NB patients and in none of the control subjects resulting in a sensitivity of 90% and a specificity of 100%. Number of NB specific OCB were 11±7 bands by photometric analyses compared to 9±5 bands by visual inspection. Validation experiments revealed an inconsistent inter-assay precision between visual and photometric analyses (NB uncoated: visual 28% versus photometric 14%, control subject uncoated: visual 16% versus photometric 24%). CONCLUSIONS: In CSF samples with positive OCB, Borrelia-specific bands were detected in almost all NB patients and in none of the control subjects. Inconsistent inter-assay precision may be explained by a poor comparability of visual and photometric approach.
Subject(s)
Borrelia burgdorferi/immunology , Cerebrospinal Fluid/immunology , Cerebrospinal Fluid/microbiology , Lyme Neuroborreliosis/cerebrospinal fluid , Lyme Neuroborreliosis/immunology , Oligoclonal Bands/cerebrospinal fluid , Oligoclonal Bands/immunology , Adult , Antigens, Bacterial/immunology , Case-Control Studies , Cross-Sectional Studies , Dementia/immunology , Female , Humans , Immunoblotting/methods , Lyme Neuroborreliosis/microbiology , Male , Middle Aged , Multiple Sclerosis/immunology , Nervous System Diseases/immunology , Nervous System Diseases/microbiology , Neuromyelitis Optica/immunology , Paraproteinemias/immunology , Retrospective Studies , Sensitivity and SpecificityABSTRACT
CANOMAD (chronic ataxic neuropathy, ophthalmoplegia, immunoglobulin M [IgM] paraprotein, cold agglutinins, and disialosyl antibodies) is a rare syndrome characterized by chronic neuropathy with sensory ataxia, ocular, and/or bulbar motor weakness in the presence of a monoclonal IgM reacting against gangliosides containing disialosyl epitopes. Data regarding associated hematologic malignancies and effective therapies in CANOMAD are scarce. We conducted a French multicenter retrospective study that included 45 patients with serum IgM antibodies reacting against disialosyl epitopes in the context of evocating neurologic symptoms. The main clinical features were sensitive symptoms (ataxia, paresthesia, hypoesthesia; n = 45, 100%), motor weakness (n = 18, 40%), ophthalmoplegia (n = 20, 45%), and bulbar symptoms (n = 6, 13%). Forty-five percent of the cohort had moderate to severe disability (modified Rankin score, 3-5). Cold agglutinins were identified in 15 (34%) patients. Electrophysiologic studies showed a demyelinating or axonal pattern in, respectively, 60% and 27% of cases. All patients had serum monoclonal IgM gammopathy (median, 2.6 g/L; range, 0.1-40 g/L). Overt hematologic malignancies were diagnosed in 16 patients (36%), with the most frequent being Waldenström macroglobulinemia (n = 9, 20%). Forty-one patients (91%) required treatment of CANOMAD. Intravenous immunoglobulins (IVIg) and rituximab-based regimens were the most effective therapies with, respectively, 53% and 52% of partial or better clinical responses. Corticosteroids and immunosuppressive drugs were largely ineffective. Although more studies are warranted to better define the optimal therapeutic sequence, IVIg should be proposed as the standard of care for first-line treatment and rituximab-based regimens for second-line treatment. These compiled data argue for CANOMAD to be included in neurologic monoclonal gammopathy of clinical significance.
Subject(s)
B-Lymphocytes/drug effects , Paraproteinemias/drug therapy , Rituximab/therapeutic use , Adrenal Cortex Hormones/therapeutic use , Adult , Aged , Aged, 80 and over , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Ataxia/drug therapy , Ataxia/etiology , Autoantibodies/blood , Autoantibodies/immunology , B-Lymphocytes/pathology , Cryoglobulins/analysis , Female , France/epidemiology , Hematologic Neoplasms/blood , Hematologic Neoplasms/drug therapy , Hematologic Neoplasms/immunology , Humans , Immunoglobulin M/blood , Immunoglobulin M/immunology , Immunoglobulins, Intravenous/therapeutic use , Immunosuppressive Agents/therapeutic use , Male , Middle Aged , Ophthalmoplegia/drug therapy , Ophthalmoplegia/etiology , Paraproteinemias/blood , Paraproteinemias/immunology , Paraproteinemias/therapy , Paresthesia/drug therapy , Paresthesia/etiology , Retrospective Studies , Syndrome , Waldenstrom Macroglobulinemia/blood , Waldenstrom Macroglobulinemia/drug therapy , Waldenstrom Macroglobulinemia/immunologyABSTRACT
To clarify the pathogenesis of anti-myelin-associated glycoprotein (MAG) antibody neuropathy associated with IgM monoclonal gammopathy (anti-MAG neuropathy), sural nerve biopsy specimens from 15 patients were investigated. Sodium channels, potassium channels, contactin-associated protein 1 (Caspr1), contactin 1, and neurofascin were evaluated by immunofluorescence in teased-fiber preparations. Immunoreactivity to the pan-sodium channel in both anti-MAG neuropathy patients and in normal controls was concentrated at the node of Ranvier unless there was demyelination, which was defined as the widening of the node of Ranvier. However, this immunoreactivity became weak or disappeared as demyelination progressed. In contrast, KCNQ2 immunostaining was nearly absent even in the absence of demyelination. The lengths of Caspr1, contactin 1, and pan-neurofascin immunostaining sites at the paranode were significantly increased compared with those of normal controls despite the absence of demyelination. The length of paranodal neurofascin staining correlated with the anti-MAG antibody titer, nerve conduction indices, the frequency of de/remyelination in teased-fiber preparations, and the frequency of widely spaced myelin (p < 0.05, p < 0.05, p < 0.01, and <0.05, respectively). These findings suggest that nodal and paranodal molecular alterations occur in early stages preceding the morphological changes associated with demyelination in anti-MAG neuropathy.
Subject(s)
Autoantibodies , Immunoglobulin M , Myelin Sheath/pathology , Myelin-Associated Glycoprotein/immunology , Paraproteinemias/pathology , Peripheral Nervous System Diseases/pathology , Sural Nerve/pathology , Aged , Aged, 80 and over , Biopsy , Female , Humans , Male , Middle Aged , Myelin Sheath/metabolism , Neural Conduction , Paraproteinemias/immunology , Paraproteinemias/metabolism , Peripheral Nervous System Diseases/immunology , Peripheral Nervous System Diseases/metabolism , Sodium Channels/metabolism , Sural Nerve/immunology , Sural Nerve/metabolismABSTRACT
The search for autoantibodies in patients with acute and chronic neuropathies has become widespread in neurological practice. These tests are more routinely available and therefore are more commonly requested in larger hospitals with neuroscience centres, although they are now also regularly requested from district general hospital settings, including by non-neurologists. However, the clinical value of these frequently expensive tests is often unclear and their impact on management not always obviously beneficial. This article reviews the main immunological tests used to search for specific autoantibodies in the setting of neuropathy and discusses their potential diagnostic importance, together with the eventual therapeutic implications of results obtained.
Subject(s)
Autoantibodies/immunology , Peripheral Nervous System Diseases/immunology , Peripheral Nervous System Diseases/pathology , Acute Disease , Chronic Disease , Humans , Paraneoplastic Syndromes/immunology , Paraneoplastic Syndromes/pathology , Paraproteinemias/immunology , Paraproteinemias/pathology , Sjogren's Syndrome/immunology , Sjogren's Syndrome/pathologyABSTRACT
INTRODUCTION: Scleromyxedema (rare cutaneous mucinosis), is characterized by the formation of lichenoid papules and presence of Serum monoclonal IgG in most cases, or all; after repeated testing. PATIENT CONCERNS: The patient is a 51-year-old male presented with thick, disfiguring elephant-like erythematous skin folds over the forehead, papular shiny eruptions over ears and trunk and waxy erythematous papules over arms and hands without dysphagia or respiratory or neurologic symptoms DIAGNOSIS: : Skin biopsy from right arm was consistent with scleromyxedema. Serum cryoglobulin was reported negative. Complete blood count and routine blood biochemistry were normal. Thyroid function tests were normal. Serum protein electrophoresis and immunofixation showed monoclonal band of 14.5âg/L typed as IgG lambda. INTERVENTIONS: Our patient was refractory to lenalidomide however improved clinically on immunoglobulins infusions on monthly basis without change in the MGUS level. OUTCOMES: NGF analysis revealed approximately 0.25% Lambda monotypic plasma cells in the bone marrow expressing CD38, CD138, and CD27 with aberrant expression of CD56 and were negative for CD45, CD19, CD117, and CD81. We also detected 0.002% circulating plasma cells (PCs) in peripheral blood. CONCLUSION: The immunophenotype of circulating tumor cells (CTCs) remain close to the malignant PCs phenotype in the BM. Hence, we report NGF approach as a novel diagnostic tool for highly sensitive MRD detection in plasma cell dyscrasias including scleromyxedema.
Subject(s)
Flow Cytometry/methods , Neoplastic Cells, Circulating/pathology , Scleromyxedema/pathology , Ear, External/pathology , Forehead/pathology , Humans , Immunoglobulin G/blood , Immunoglobulins, Intravenous/administration & dosage , Immunoglobulins, Intravenous/therapeutic use , Male , Middle Aged , Paraproteinemias/immunology , Paraproteinemias/pathology , Scleromyxedema/therapy , Skin/pathologySubject(s)
Choroid Diseases/immunology , Conjunctival Diseases/immunology , Histiocytosis, Non-Langerhans-Cell/diagnosis , Paraproteinemias/diagnosis , Aged , Biopsy , Choroid/pathology , Choroid Diseases/diagnosis , Choroid Diseases/drug therapy , Conjunctival Diseases/diagnosis , Conjunctival Diseases/drug therapy , Fatal Outcome , Histiocytosis, Non-Langerhans-Cell/drug therapy , Histiocytosis, Non-Langerhans-Cell/immunology , Humans , Immunoglobulins, Intravenous/administration & dosage , Male , Paraproteinemias/complications , Paraproteinemias/drug therapy , Paraproteinemias/immunology , Skin/pathologyABSTRACT
BACKGROUND: Cryoglobulins and hyperviscosity syndrome (HS) sometimes occur in multiple myeloma (MM), which are considered clinical emergencies. In laboratory practice, aspiration failure in routine blood tests sometimes occurs when the sample is inadequate. Here, a case of cryoglobulinemia and HS associated with advanced multiple myeloma was reported, which unusually is initially confirmed by aspiration failure in a routine blood test with sufficient sample. METHODS: A case of a 48-year-old female whose diagnosis of cryoglobulinemia and hyperviscosity syndrome secondary to MM-IgA kappa was confirmed from routine blood test. RESULTS: The sufficient sample for routine blood test could not be analyzed in a hematology analyzer due to aspiration failure, which was found to be caused by high viscosity and poor liquidity. A peripheral blood smear showed numerous non-cellular clouds, erythrocyte rouleaux formation, and plasma cell infiltration. After a water bath, the non-cellular clouds evidently disappeared, and the routine blood test was successfully conducted. Centrifugation of the sample for biochemical test, which had previously failed, was also possible. The case was confirmed as complications of cryoglobulinemia and HS associated with advanced MM, and the non-cellular clouds were identified as cryoglobulins. CONCLUSIONS: This case report provides an effective way for clinicians to deal with this kind of abnormal sample and limited but important laboratory evidence to establish early diagnosis of cryoglobulinemia and HS secondary to MM.
Subject(s)
Blood Viscosity , Cryoglobulinemia , Diagnostic Tests, Routine/methods , Hypergammaglobulinemia , Immunoglobulin A/blood , Immunoglobulin kappa-Chains/blood , Multiple Myeloma , Paraproteinemias , Cryoglobulinemia/diagnosis , Cryoglobulinemia/etiology , Cryoglobulinemia/immunology , Early Diagnosis , Female , Hematologic Tests/methods , Humans , Hypergammaglobulinemia/blood , Hypergammaglobulinemia/diagnosis , Middle Aged , Multiple Myeloma/blood , Multiple Myeloma/pathology , Paraproteinemias/diagnosis , Paraproteinemias/immunology , SyndromeABSTRACT
A 74-year-old man presented with nephrotic syndrome and kidney insufficiency. Laboratory tests revealed monoclonal gammopathy of immunoglobulin A-lambda. Renal biopsy revealed diffuse mesangial proliferation and double-contoured basement membranes. Immunofluorescent analyses showed granular deposition of immunoglobulin A and C3 at the capillary walls and mesangial regions. Immunohistochemistry suggested monoclonal deposition of immunoglobulin A1-lambda. Electron microscopic analyses showed finely granular electron-dense deposits at mesangial and subendothelial areas. These findings suggested immunoglobulin A-type proliferative glomerulonephritis with monoclonal immunoglobulin deposits. Based on the results of bone marrow aspiration, multiple myeloma was diagnosed. Because the renal manifestation was considered to be affected by monoclonal gammopathy, chemotherapy was initiated rather than immunomodulatory therapy. Although bortezomib and dexamethasone proved ineffective, second chemotherapy with elotuzumab, lenalidomide, and dexamethasone was successful, and kidney function recovered. Effective treatments for proliferative glomerulonephritis with monoclonal immunoglobulin deposits have not been established. This represents the first description of a patient successfully treated for proliferative glomerulonephritis with monoclonal immunoglobulin deposits by chemotherapy using elotuzumab.